Integra LifeSciences (NASDAQ:IART) Cut to Hold at Wall Street Zen

Wall Street Zen cut shares of Integra LifeSciences (NASDAQ:IART) from a buy rating to a hold rating in a research report released on Saturday,Wall Street Zen reports.

A number of other brokerages have also recently issued reports on IART. Truist Financial raised shares of Integra LifeSciences to a “hold” rating in a report on Thursday, October 1st. Wells Fargo & Company upped their price target on Integra LifeSciences from $15.00 to $18.00 and gave the stock an “equal weight” rating in a report on Thursday, July 30th. UBS Group began coverage on Integra LifeSciences in a research note on Tuesday, July 28th. They issued a “neutral” rating and a $19.00 price objective for the company. Citigroup reaffirmed a “neutral” rating and set a $19.00 price objective (up from $16.00) on shares of Integra LifeSciences in a report on Wednesday, July 8th. Finally, Argus upgraded Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 target price on the stock in a research report on Thursday, June 18th. One equities research analyst has rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Reduce” and an average price target of $17.29.

Integra LifeSciences Trading Up 4.8%

NASDAQ:IART opened at $13.29 on Friday. Integra LifeSciences has a 1 year low of $8.70 and a 1 year high of $20.49. The company has a debt-to-equity ratio of 1.75, a quick ratio of 2.11 and a current ratio of 3.60. The stock has a fifty day moving average price of $16.56 and a two-hundred day moving average price of $15.22. The stock has a market capitalization of $1.03 billion, a price-to-earnings ratio of -147.65, a PEG ratio of 0.65 and a beta of 1.21.

Integra LifeSciences (NASDAQ:IART) last issued its earnings results on Wednesday, July 29th. The life sciences company reported $0.56 EPS for the quarter, topping the consensus estimate of $0.48 by $0.08. The company had revenue of $418.76 million for the quarter, compared to analyst estimates of $417.54 million. Integra LifeSciences had a negative net margin of 0.44% and a positive return on equity of 18.30%. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. As a group, sell-side analysts anticipate that Integra LifeSciences will post 2.45 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Sequoia Financial Advisors LLC lifted its position in Integra LifeSciences by 27.4% in the 1st quarter. Sequoia Financial Advisors LLC now owns 14,233 shares of the life sciences company’s stock valued at $134,000 after purchasing an additional 3,059 shares during the last quarter. State of Wyoming grew its position in Integra LifeSciences by 26.3% in the 4th quarter. State of Wyoming now owns 19,998 shares of the life sciences company’s stock worth $248,000 after purchasing an additional 4,168 shares during the last quarter. Public Employees Retirement System of Ohio acquired a new stake in shares of Integra LifeSciences in the second quarter valued at approximately $82,000. Integrated Wealth Concepts LLC acquired a new stake in shares of Integra LifeSciences in the second quarter valued at approximately $84,000. Finally, Amundi raised its holdings in shares of Integra LifeSciences by 80.8% during the first quarter. Amundi now owns 19,430 shares of the life sciences company’s stock valued at $183,000 after buying an additional 8,681 shares during the last quarter. 84.78% of the stock is owned by hedge funds and other institutional investors.

More Integra LifeSciences News

Here are the key news stories impacting Integra LifeSciences this week:

• Positive Sentiment: Truist Financial upgraded Integra LifeSciences, providing some support for the stock and suggesting improved analyst sentiment. Integra LifeSciences Upgraded at Truist Financial
• Positive Sentiment: BMO Capital Markets lowered its price target to $15 from $18 but retained a “market perform” rating. The revised target remains above the referenced share price, indicating analysts see potential recovery despite reduced expectations. Integra LifeSciences Stock Price Target Lowered at BMO Capital Markets
• Neutral Sentiment: Johnson Fistel announced an investigation into Integra on behalf of investors following the company’s flooding-related outlook cuts and reported 21% stock decline. The announcement does not establish wrongdoing, but it could add legal and reputational uncertainty. Johnson Fistel Investor Alert
• Negative Sentiment: Integra announced preliminary third-quarter 2026 results that include an adverse impact from flooding at its Cincinnati operations and cut its 2026 financial guidance. The disruption raises concerns about near-term revenue, earnings and production performance, making this the primary fundamental headwind for IART. Integra LifeSciences Preliminary Q3 Results and Flooding Impact

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation (NASDAQ:IART) is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery, and orthopedic procedures. Its offerings are designed to help physicians treat neurological conditions, traumatic injuries, complex wounds, and other surgical needs.

The company’s products include dural repair and regeneration materials, cerebrospinal fluid management systems, surgical instruments, nerve and tendon repair products, and tissue-engineered solutions for wound care and reconstructive surgery.